Clinical trials: Metformin
Non-alcoholic Steatohepatitis
A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
This is a double-blind, placebo-controlled study in adults with non-alcoholic steatohepatitis and Type 2 Diabetes Mellitis on stable dose of metformin monotherapy.
- Trial name
- NCT03969719
- Testing
- PF-06835919
- Where
- 106 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus
This is a 26-week, multicenter, randomized, double-blind, placebo and active comparator-controlled, parallel-group study in participants with type 2 diabetes currently sub-optimally controlled by diet and exercise or with…
- Trial name
- NCT00571519
- Testing
- Rivoglitazone HCl, pioglitazone HCl, pioglitazone HCl 45 mg
- Where
- 18 sites in United States
- Volunteers
- 94 people
- Sponsor
- Daiichi Sankyo
Diabetes Type 2
Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus
Randomized, double-blind, placebo-controlled, parallel group study.
- Trial name
- NCT02496000
- Testing
- ORMD-0801
- Where
- 34 sites in United States
- Volunteers
- 188 people
- Sponsor
- Oramed, Ltd.
Breast Cancer
Pre-Surgical Study: Effect of Metformin on Breast Cancer Proliferation
The purpose of this pilot study is to use a pre surgical intervention model to evaluate the biologic effects of metformin in women with newly diagnosed early invasive breast cancer.
- Trial name
- NCT00930579
- Testing
- Metformin
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Columbia University
Polycystic Ovary Syndrome, Disorder of Glucose Regulation
Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis
The objective of the present proposal is to compare the clinical, endocrine and metabolic effects of therapy with combination saxagliptin and metformin to saxagliptin and metformin monotherapy in women with PCOS and prediabetic…
- Trial name
- BMS-AZPCOS (NCT02022007)
- Testing
- Metformin XR, Saxagliptin, Saxagliptin-Metformin XR
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Woman's
Type 2 Diabetes Mellitus
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes
Metabolic defects contributing to the development of type 2 diabetes (T2D) are relative insulin insufficiency and insulin resistance that are associated with a cluster of abnormalities that increase the risk for cardiovascular…
- Trial name
- NCT01156597
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Miami
Diabetes
A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
This clincial trial is evaluating if the co-administration of saxagliptin and dapagliflozin, in addition to metformin, results in better glycemic control, as measured by HbA1c, over a treatment period of 52 weeks, compared to the…
- Trial name
- NCT02419612
- Testing
- Saxagliptin, Dapagliflozin, Glimepiride
- Where
- 84 sites in United States, Czechia and 8 more
- Volunteers
- 444 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs
This trial is conducted in Africa. The aim of this clinical trial is to investigate the effect of 50 weeks of treatment with different intensified insulin administrations (all in combination with a fixed dose of metformin) on…
- Trial name
- NCT01068652
- Testing
- insulin detemir, insulin aspart, biphasic insulin aspart 30
- Where
- 19 sites in Algeria, Egypt and 3 more
- Volunteers
- 403 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
Primary objective: To evaluate the effect of lixisenatide versus placebo over a period of 24 weeks on glycemic control, as evaluated by glycosylated hemoglobin (HbA1c) reduction, in older type 2 diabetes participants (T2DM) who…
- Trial name
- GetGoal-O (NCT01798706)
- Testing
- Lixisenatide (AVE0010), Antidiabetic background therapy
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 350 people
- Sponsor
- Sanofi
Psychotic Disorders
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
- Trial name
- IMPACT (NCT00806234)
- Testing
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Johns Hopkins University
Diabetes Mellitus, Type 2, Obesity
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
This trial will evaluate use of BI 10773 as add-on to insulin regimen alone or with metformin in patients with typr 2 diabetes. Both lowering glucose and HbA1c and reducing the use of insulin in this population would provide…
- Trial name
- NCT01306214
- Testing
- BI 10773
- Where
- 103 sites in United States, Belgium and 12 more
- Volunteers
- 566 people
- Sponsor
- Boehringer Ingelheim
Diabetes
Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM
In patients with type 2 diabetes with inadequate glycemic control on diet and exercise after 6 weeks of treatment: Objective: To assess the effects of co-administration of sitagliptin and metformin compared to placebo on hepatic…
- Trial name
- NCT00820573
- Testing
- Sitagliptin, Metformin, Sitagliptin + Metformin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
The purpose of this study is to look at the effect that the study drug OPC has on AGE levels in patients with prostate cancer.
- Trial name
- NCT02946996
- Testing
- Metformin, OPC
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Medical University of South Carolina
Interaction, Endogenous Biomarkers
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters
The objective of this study is to confirm the feasibility of using a panel of endogenous substrates/metabolites as a robust biomarker of OCTs and OATs by conducting a controlled, comprehensive clinical drug-drug interaction study…
- Trial name
- NCT05365451
- Testing
- MetFORMIN Oral Solution, Cimetidine 400 MG, Furosemide Oral Liquid Product
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Washington State University
Type 2 Diabetes Treated With Insulin
Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects
The aim of the study was to compare the pharmacodynamic properties of different doses of regular human insulin administered in capsule form twice daily in a randomised twelve-week open-label trial.
- Trial name
- NCT06473662
- Testing
- Oral insulin
- Where
- United Kingdom
- Volunteers
- 153 people
- Sponsor
- Roger New
Type 2 Diabetes Mellitus
Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)
To demonstrate bioequivalence of a 2.5 mg saxagliptin/500 mg metformin (glucophage) immediate release (IR) fixed dose combination (FDC) tablet to the 2.5 mg saxagliptin tablet and 500 mg metformin IR tablet co-administered to…
- Trial name
- NCT00899470
- Testing
- Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
PreDiabetes, Impaired Fasting Glucose (IFG)
Metformin and Its Impact on the Substances Associated With NO Production in Prediabetes Patients.
This study evaluates the effect of different doses of metformin on the function of endothelium in people with pre-diabetes. One group of the patients will receive metformin in dose: 1500 mg, the second one will receive 3000…
- Conditions
- PreDiabetes, Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT)
- Trial name
- NCT03398356
- Testing
- Metformin
- Where
- Poland
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wroclaw Medical University
Low Back Pain
Effects of Metformin on Low Back Pain
The purpose of the current study is to determine the effects of metformin in non-diabetic patients with low back pain, and identify novel targets for future treatments
- Trial name
- NCT04055012
- Testing
- Metformin
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Gwendolyn Sowa
Type 2 Diabetes
Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin
The purpose of this study is to investigate the efficacy and safety of Cycloset® and placebo when added to metformin monotherapy (at least 1000 mg/day for 3 months prior to screening) in persons with type 2 diabetes mellitus who…
- Trial name
- NCT00441363
- Testing
- Bromocriptine Mesylate
- Volunteers
- 66 people
- Sponsor
- VeroScience
Inflammatory Response
Effects of Metformin in a Non-Diabetic Patient Population
Metformin has a well-established safety profile and it has become clear that metformin has additional salutary effects, including anti-inflammatory, anti-aging, and anti-thrombotic properties.
- Trial name
- NCT03772964
- Testing
- MetFORMIN Hydrochloride ER
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Brian Zuckerbraun